

NERVIANO MEDICAL SCIENCES

PART OF NMS GROUP

Nerviano Medical Sciences S.r.l. names Salvatore Marengoni Galdy, M.D., Global Clinical Lead

NERVIANO, 31 October 2022 – Nerviano Medical Sciences Srl (NMS Srl), a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, today announced that Salvatore Marengoni Galdy, M.D., has joined the Global Clinical Development Team as Global Clinical Lead, effective immediately. Dr. Galdy will drive values of our assets through planning and leading the clinical development to meet all time, quality, budget, Company standards and scientific requirements.

“We are excited to welcome Salvatore to our Global Clinical Development team at this important moment for our company, as several of our co-lead programs enter global clinical trials,” said Lisa Mahnke, M.D., PhD, Board Member and Chief Medical Officer* of NMS Srl and Managing director of Nerviano Medical Sciences Inc., the US subsidiary. “Salvatore brings a breadth of global drug development experience making him an invaluable contributor to the company as we advance our clinical assets for patients currently with limited options.”

Dr. Galdy commented: “My years of being deeply involved in the oncology field gives me the opportunity to understand the urgent need and the importance to deliver new therapeutics. I am honored to work alongside such a patient-focused team and look forward to advance our innovative pipeline together with all our Global Clinical Development colleagues.”

Dr. Galdy joins us from Oncology Clinical Practice at Valle Olona hospital. Prior to that he was with Bayer SpA, Milan, as Clinical Development Leader. He has a range of research and clinical experiences including the European Institute of Oncology in Milan, Bergamo and Parma Hospitals. He completed Medical Oncology clinical residency at the University of Parma at which he took his medical degree. He has a long publication history with a variety of treatments and cancer pathways including HER2/HER3, mTOR, RAF, pembrolizumab, ramucirumab, platin, temozolomide, sunitinib and more. He has published in colorectal, gastric, biliary tract carcinomas and neuroendocrine tumors.

*consultant

About Nerviano Medical Sciences

[Nerviano Medical Sciences](#) S.r.l. (NMS Srl) is focused on discovery and clinical development of small-molecule new chemical entities (NCEs) for oncology. We take innovative approaches on novel mechanisms of action and drug targets to bring first- and best-in-class personalized medicines to cancer patients. Our current pipeline consists of NCEs originating from our well validated kinase platform that span from early preclinical to clinical stage projects and which are being developed both in-house and with partners.

NMS Srl combines the flexibility of a biotech with the quality of a big pharma. Our experienced management team leads a highly skilled staff of professionals with global vision and a broad range of expertise in research, drug discovery and clinical development. We cover the whole range of additional aspects of drug development through the NMS Group affiliate companies, Accelera (AdMet) and NerPharMa (manufacturing).

A key strength is our industrially renowned kinase inhibitor drug discovery platform which comprises an ever-evolving chemical collection with broad intellectual property coverage, discovery know-how and technologies which enabled us to out-license IP rights on recently approved innovative medicines such as encorafenib and entrectinib.

NERVIANO MEDICAL SCIENCES

PART OF NMS GROUP

We collaborate with academia and clinical investigators as well as with industrial partners worldwide to advance our programs from early discovery to clinical development of new drugs. We seek further strategic collaborations to develop and commercialize our products in different territories as well as in-licensing opportunities of promising assets for clinical development.

About NMS Group

[NMS Group](#) is the largest oncological R&D company in Italy. More than half of our 400 employees are highly educated individuals dedicated to innovative research, development and manufacturing. The NMS kinase inhibitor discovery platform as well as the antibody-conjugating payload platform are the driving forces of the group's innovation, securing global recognition of NMS in personalized therapy. Recently entrectinib, originally discovered by NMS, is a targeted kinase inhibitor to treat NTRK1/2/3 and ROS1 dependent solid tumors that was licensed to Ignyta, now a member of the Roche Group, gained approvals for commercialization in all major markets. This is further evident of the competitiveness of the drug discovery platform of NMS Group.

NMS Group has three subsidiaries. NMS S.r.l. is a FIC / BIC focused drug research and development company with a robust pipeline of more than a dozen anti-cancer projects, and three of the projects are currently in early clinical development. The other two subsidiaries are Accelera, which is a preclinical CRO company, and NerPharMa which manufactures API and drug products supporting clinical developments and commercialization.

Media contact: Sidney Dung Sidney.dung@nmsgroup.it